Corever in the Treatment of Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 134 participants.

Also called NCT02432937

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 134 participants (enrolled count) (from the registry)
Sponsor
TSH Biopharm Corporation Limited (from the registry)
Registry
  • NCT NCT02432937
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02432937. Randomized; double masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Corever in the Treatment of Hypertension
Condition
Hypertension
Intervention (Drug)
Corever
Lead sponsor
TSH Biopharm Corporation Limited (class: industry)

Record details

Record id
cardio:ct-nct02432937
Content hash
6adf318301e0dc3bd0de07d13dd72ea90febeab98f8b90d0373d611f97f459a8